{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:09:59Z","timestamp":1793801399557,"version":"4.6.1"},"reference-count":208,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07582-0","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:34:53Z","timestamp":1768397693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chimeric antigen receptor T\u2011cell therapy in chronic viral infections: a review"],"prefix":"10.1186","volume":"24","author":[{"given":"Qiyang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4300-0900","authenticated-orcid":false,"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"2","key":"7582_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","volume":"14","author":"JS Marshall","year":"2018","unstructured":"Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol. 2018;14(2):49.","journal-title":"Allergy, Asthma Clin Immunol"},{"issue":"12","key":"7582_CR2","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1093\/cid\/civ197","volume":"60","author":"GJ Dore","year":"2015","unstructured":"Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of \u201cperfectovir\u201d. Clin Infect Dis. 2015;60(12):1829\u201336.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"7582_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s12072-024-10640-2","volume":"18","author":"W Xiao","year":"2024","unstructured":"Xiao W, Zhao J, Chen Y, Liu X, Xu C, Zhang J, et al. Global burden and trends of acute viral hepatitis among children and adolescents from 1990 to 2019: a systematic analysis of the global burden of disease study 2019. Hepatol Int. 2024;18(3):917\u201328.","journal-title":"Hepatol Int"},{"key":"7582_CR4","doi-asserted-by":"crossref","unstructured":"De Melo Silva J, Pinheiro-Silva R, Dhyani A, Pontes GS. Cytomegalovirus and Epstein-Barr infections: prevalence and impact on patients with hematological diseases. Biomed Res Int. 2020;2020:1627824.","DOI":"10.1155\/2020\/1627824"},{"issue":"1","key":"7582_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 2023;21(1):449.","journal-title":"J Transl Med"},{"key":"7582_CR6","doi-asserted-by":"crossref","unstructured":"Liu B, Zhang W, Xia B, Jing S, Du Y, Zou F, et al. Broadly neutralizing antibody-derived car T cells reduce viral reservoir in individuals infected with HIV-1. J Clin Invest. 2021;131(19).","DOI":"10.1172\/JCI150211"},{"issue":"2","key":"7582_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11904-018-0388-x","volume":"15","author":"TA Wagner","year":"2018","unstructured":"Wagner TA. Quarter century of anti-HIV car T cells. Curr HIV\/AIDS Rep. 2018;15(2):147\u201354.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"7582_CR8","doi-asserted-by":"publisher","first-page":"873701","DOI":"10.3389\/fimmu.2022.873701","volume":"13","author":"J York","year":"2022","unstructured":"York J, Gowrishankar K, Micklethwaite K, Palmer S, Cunningham AL, Nasr N. Evolving strategies to eliminate the CD4 T cells HIV viral reservoir via car T cell immunotherapy. Front Immunol. 2022;13:873701.","journal-title":"Front Immunol"},{"key":"7582_CR9","doi-asserted-by":"publisher","first-page":"115750","DOI":"10.1016\/j.biopha.2023.115750","volume":"168","author":"E Mu\u00f1oz-Muela","year":"2023","unstructured":"Mu\u00f1oz-Muela E, Trujillo-Rodr\u00edguez M, Serna-Gallego A, Saborido-Alconchel A, Ruiz-Mateos E, L\u00f3pez-Cort\u00e9s LF, et al. HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors. Biomed Pharmacother. 2023;168:115750.","journal-title":"Biomed Pharmacother"},{"key":"7582_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.virol.2023.06.015","volume":"586","author":"G Guo","year":"2023","unstructured":"Guo G, He W, Zhou Z, Diao Y, Sui J, Li W. PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice. Virology. 2023;586:23\u201334.","journal-title":"Virology"},{"key":"7582_CR11","doi-asserted-by":"publisher","first-page":"1289303","DOI":"10.3389\/fimmu.2024.1289303","volume":"15","author":"E Morte-Romea","year":"2024","unstructured":"Morte-Romea E, Pesini C, Pellejero-Sagastizabal G, Letona-Gimenez S, Martinez-Lostao L, Aranda SL, et al. CAR immunotherapy for the treatment of infectious diseases: a systematic review. Front Immunol. 2024;15:1289303.","journal-title":"Front Immunol"},{"issue":"1","key":"7582_CR12","doi-asserted-by":"publisher","first-page":"iqad006","DOI":"10.1093\/oxfimm\/iqad006","volume":"4","author":"E Jenkins","year":"2023","unstructured":"Jenkins E, Whitehead T, Fellermeyer M, Davis SJ, Sharma S. The current state and future of T-cell exhaustion research. Oxf Open Immunol. 2023;4(1):iqad006.","journal-title":"Oxf Open Immunol"},{"key":"7582_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","volume":"9","author":"G Schonrich","year":"2019","unstructured":"Schonrich G, Raftery MJ. The PD-1\/PD-L1 Axis and virus infections: a delicate Balance. Front Cell Infect Microbiol. 2019;9:207.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"7582_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","volume":"27","author":"LB Cohn","year":"2020","unstructured":"Cohn LB, Chomont N, Deeks SG. The biology of the HIV-1 latent reservoir and implications for cure strategies. Cell Host Microbe. 2020;27(4):519\u201330.","journal-title":"Cell Host Microbe"},{"key":"7582_CR15","doi-asserted-by":"publisher","first-page":"37021","DOI":"10.1038\/srep37021","volume":"6","author":"BS Dirk","year":"2016","unstructured":"Dirk BS, Pawlak EN, Johnson AL, Van Nynatten LR, Jacob RA, Heit B, et al. HIV-1 Nef sequesters MHC-I intracellularly by targeting early stages of endocytosis and recycling. Sci Rep. 2016;6:37021.","journal-title":"Sci Rep"},{"issue":"2","key":"7582_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","volume":"145","author":"K Krebs","year":"2013","unstructured":"Krebs K, B\u00f6ttinger N, Huang LR, Chmielewski M, Arzberger S, Gasteiger G, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology. 2013;145(2):456\u201365.","journal-title":"Gastroenterology"},{"key":"7582_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","volume":"9","author":"G Sch\u00f6nrich","year":"2019","unstructured":"Sch\u00f6nrich G, Raftery MJ. The PD-1\/PD-L1 axis and virus infections: a delicate Balance. Front Cell Infect Microbiol. 2019;9:207.","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"7582_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0042-6822(02)00055-7","volume":"306","author":"ME Severino","year":"2003","unstructured":"Severino ME, Sarkis PT, Walker BD, Yang OO. Chimeric immune receptor T cells bypass class I requirements and recognize multiple cell types relevant in HIV-1 infection. Virology. 2003;306(2):371\u201375.","journal-title":"Virology"},{"key":"7582_CR19","doi-asserted-by":"crossref","unstructured":"Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci Transl Med. 2019;11(504).","DOI":"10.1126\/scitranslmed.aav5685"},{"key":"7582_CR20","doi-asserted-by":"publisher","first-page":"1546172","DOI":"10.3389\/fimmu.2025.1546172","volume":"16","author":"S G\u00f3mez-Melero","year":"2025","unstructured":"G\u00f3mez-Melero S, Hassouneh F, Vallejo-Berm\u00fadez IM, Ag\u00fcera-Morales E, Solana R, Caballero-Villarraso J. Tandem CAR-T cell therapy: recent advances and current challenges. Front Immunol. 2025;16:1546172.","journal-title":"Front Immunol"},{"issue":"4","key":"7582_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41579-020-00449-9","volume":"19","author":"JE Jones","year":"2021","unstructured":"Jones JE, Le Sage V, Lakdawala SS. Viral and host heterogeneity and their effects on the viral life cycle. Nat Rev Microbiol. 2021;19(4):272\u201382.","journal-title":"Nat Rev Microbiol"},{"key":"7582_CR22","doi-asserted-by":"publisher","first-page":"1321596","DOI":"10.3389\/fimmu.2023.1321596","volume":"14","author":"DC Harrer","year":"2023","unstructured":"Harrer DC, Li SS, Kaljanac M, Barden M, Pan H, Abken H. Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges. Front Immunol. 2023;14:1321596.","journal-title":"Front Immunol"},{"key":"7582_CR23","doi-asserted-by":"crossref","unstructured":"Del Rio C, Dzau V. The urgent case for recommitting to global HIV\/AIDS goals. JAMA. 2024.","DOI":"10.1001\/jama.2024.26348"},{"key":"7582_CR24","doi-asserted-by":"publisher","first-page":"100965","DOI":"10.1016\/j.blre.2022.100965","volume":"55","author":"X Chen","year":"2022","unstructured":"Chen X, Jia L, Zhang X, Zhang T, Zhang Y. One arrow for two targets: potential co-treatment regimens for lymphoma and HIV. Blood Rev. 2022;55:100965.","journal-title":"Blood Rev"},{"issue":"1","key":"7582_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","volume":"10","author":"Y Mao","year":"2024","unstructured":"Mao Y, Liao Q, Zhu Y, Bi M, Zou J, Zheng N, et al. Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study. Cell Discov. 2024;10(1):49.","journal-title":"Cell Discov"},{"key":"7582_CR26","doi-asserted-by":"crossref","unstructured":"Beck SE, Blankson JN. Replacing cART with CAR-T cells: using immunotherapy to cure HIV. Mol Ther. 2020;28(7):1561\u201362.","DOI":"10.1016\/j.ymthe.2020.06.008"},{"issue":"11","key":"7582_CR27","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","volume":"26","author":"CR Maldini","year":"2020","unstructured":"Maldini CR, Claiborne DT, Okawa K, Chen T, Dopkin DL, Shan X, et al. Dual CD4-based car T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. Nat Med. 2020;26(11):1776\u201387.","journal-title":"Nat Med"},{"issue":"10","key":"7582_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.4049\/immunohorizons.2200073","volume":"6","author":"EK Cartwright","year":"2022","unstructured":"Cartwright EK, Pampusch MS, Rendahl AK, Berger EA, Coleman-Fuller N, Skinner PJ. HIV-specific CAR T cells with CD28 or 4-1BB signaling domains are phenotypically and functionally distinct and effective at suppressing HIV and simian immunodeficiency virus. Immunohorizons. 2022;6(10):693\u2013704.","journal-title":"Immunohorizons"},{"key":"7582_CR29","doi-asserted-by":"crossref","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221(2).","DOI":"10.1084\/jem.20230903"},{"issue":"13","key":"7582_CR30","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.1128\/JVI.00474-15","volume":"89","author":"L Liu","year":"2015","unstructured":"Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol. 2015;89(13):6685\u201394.","journal-title":"J Virol"},{"key":"7582_CR31","doi-asserted-by":"crossref","unstructured":"Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci Transl Med. 2019;11(504).","DOI":"10.1126\/scitranslmed.aav5685"},{"key":"7582_CR32","doi-asserted-by":"crossref","unstructured":"Anthony-Gonda K, Ray A, Su H, Wang Y, Xiong Y, Lee D, et al. In vivo killing of primary HIV-infected cells by peripheral-injected early memory-enriched anti-HIV duoCAR T cells. JCI Insight. 2022;7(21).","DOI":"10.1172\/jci.insight.161698"},{"issue":"4","key":"7582_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/ID9.0000000000000129","volume":"4","author":"X Wang","year":"2024","unstructured":"Wang X, Liu J, Hao F, Ajavavarakula T, Shi X. CAR-T therapy in HIV: pioneering advances and Navigating challenges. Infect Dis Immun. 2024;4(4):194\u2013205.","journal-title":"Infect Dis Immun"},{"key":"7582_CR34","doi-asserted-by":"crossref","unstructured":"Ollerton MT, Berger EA, Connick E, Burton GF. HIV-1-Specific chimeric antigen receptor T cells fail to recognize and eliminate the follicular dendritic cell HIV reservoir in vitro. J Virol. 2020;94(10).","DOI":"10.1128\/JVI.00190-20"},{"issue":"3","key":"7582_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcyt.2017.11.001","volume":"20","author":"MH Ghanem","year":"2018","unstructured":"Ghanem MH, Bolivar-Wagers S, Dey B, Hajduczki A, Vargas-Inchaustegui DA, Danielson DT, et al. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity. Cytotherapy. 2018;20(3):407\u201319.","journal-title":"Cytotherapy"},{"key":"7582_CR36","doi-asserted-by":"publisher","first-page":"1032537","DOI":"10.3389\/fimmu.2022.1032537","volume":"13","author":"BC Davey","year":"2022","unstructured":"Davey BC, Pampusch MS, Cartwright EK, Abdelaal HM, Rakasz EG, Rendahl A, et al. Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR\/CXCR5 T cells. Front Immunol. 2022;13:1032537.","journal-title":"Front Immunol"},{"key":"7582_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fcimb.2020.00242","volume":"10","author":"A Hajduczki","year":"2020","unstructured":"Hajduczki A, Danielson DT, Elias DS, Bundoc V, Scanlan AW, Berger EA. A trispecific anti-HIV chimeric antigen receptor containing the CCR5 N-Terminal region. Front Cell Infect Microbiol. 2020;10:242.","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"7582_CR38","first-page":"3053","volume":"109","author":"R Urak","year":"2024","unstructured":"Urak R, Pahlavanneshan S, Gittins B, Nakamura R, Zaia JA, Baird JH, et al. Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells. Haematologica. 2024;109(9):3053\u201358.","journal-title":"Haematologica"},{"issue":"5","key":"7582_CR39","doi-asserted-by":"publisher","first-page":"e0193324","DOI":"10.1128\/jvi.01933-24","volume":"99","author":"C Wu","year":"2025","unstructured":"Wu C, Johnson NM, Yu S, Lo AS, Sahu GK, Marx PA, et al. Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy. J Virol. 2025;99(5):e0193324.","journal-title":"J Virol"},{"key":"7582_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fimmu.2018.00020","volume":"9","author":"MP Bronnimann","year":"2018","unstructured":"Bronnimann MP, Skinner PJ, Connick E. The B-cell follicle in HIV infection: barrier to a cure. Front Immunol. 2018;9:20.","journal-title":"Front Immunol"},{"issue":"5","key":"7582_CR41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.chom.2016.04.008","volume":"19","author":"PM Lieberman","year":"2016","unstructured":"Lieberman PM. Epigenetics and genetics of viral latency. Cell Host Microbe. 2016;19(5):619\u201328.","journal-title":"Cell Host Microbe"},{"issue":"2","key":"7582_CR42","doi-asserted-by":"publisher","first-page":"100073","DOI":"10.1016\/j.jve.2022.100073","volume":"8","author":"MC Choudhary","year":"2022","unstructured":"Choudhary MC, Cyktor JC, Riddler SA. Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir. J Virus Erad. 2022;8(2):100073.","journal-title":"J Virus Erad"},{"key":"7582_CR43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fimmu.2018.00492","volume":"9","author":"KP Haran","year":"2018","unstructured":"Haran KP, Hajduczki A, Pampusch MS, Mwakalundwa G, Vargas-Inchaustegui DA, Rakasz EG, et al. Simian immunodeficiency virus (SIV)-specific chimeric antigen receptor-T cells engineered to target B cell follicles and suppress SIV replication. Front Immunol. 2018;9:492.","journal-title":"Front Immunol"},{"key":"7582_CR44","doi-asserted-by":"crossref","unstructured":"Eichholz K, Fukazawa Y, Peterson CW, Haeseleer F, Medina M, Hoffmeister S, et al. Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers. J Clin Invest. 2024;134(7).","DOI":"10.1172\/JCI169309"},{"key":"7582_CR45","doi-asserted-by":"crossref","unstructured":"Rothemejer FH, Lauritsen NP, Juhl AK, Schleimann MH, K\u00f6nig S, S\u00f8gaard OS, et al. Development of HIV-resistant CAR T cells by CRISPR\/Cas-mediated CAR integration into the CCR5 locus. Viruses. 2023;15(1).","DOI":"10.3390\/v15010202"},{"issue":"3","key":"7582_CR46","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","volume":"25","author":"M Hale","year":"2017","unstructured":"Hale M, Mesojednik T, Romano Ibarra GS, Sahni J, Bernard A, Sommer K, et al. Engineering HIV-Resistant, anti-HIV chimeric antigen receptor T cells. Mol Ther. 2017;25(3):570\u201379.","journal-title":"Mol Ther"},{"key":"7582_CR47","doi-asserted-by":"publisher","first-page":"1590690","DOI":"10.3389\/fimmu.2025.1590690","volume":"16","author":"JW Wang","year":"2025","unstructured":"Wang JW, Liu JH, Xun JJ. CCR5 gene editing and HIV immunotherapy: current understandings, challenges, and future directions. Front Immunol. 2025;16:1590690.","journal-title":"Front Immunol"},{"issue":"5","key":"7582_CR48","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/COH.0000000000000963","volume":"20","author":"MA Moso","year":"2025","unstructured":"Moso MA, Roche M, Cevaal PM, Lewin SR. CRISPR\/Cas9 for achieving postintervention HIV control. Curr Opin HIV AIDS. 2025;20(5):432\u201340.","journal-title":"Curr Opin HIV AIDS"},{"key":"7582_CR49","doi-asserted-by":"crossref","unstructured":"Hale M, Lee B, Honaker Y, Leung WH, Grier AE, Jacobs HM, et al. Homology-directed recombination for enhanced Engineering of chimeric antigen receptor T cells. Mol Ther methods Clin Dev. 2017;4:192\u2013203.","DOI":"10.1016\/j.omtm.2016.12.008"},{"issue":"307","key":"7582_CR50","doi-asserted-by":"publisher","first-page":"307ra156","DOI":"10.1126\/scitranslmed.aac5530","volume":"7","author":"BD Sather","year":"2015","unstructured":"Sather BD, Romano Ibarra GS, Sommer K, Curinga G, Hale M, Khan IF, et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med. 2015;7(307):307ra156.","journal-title":"Sci Transl Med"},{"issue":"3","key":"7582_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbrc.2015.05.026","volume":"463","author":"M Kamata","year":"2015","unstructured":"Kamata M, Kim PY, Ng HL, Ringpis GE, Kranz E, Chan J, et al. Ectopic expression of anti-HIV-1 shRANs protects CD8(+) T cells modified with CD4\u03b6 CAR from HIV-1 infection and alleviates impairment of cell proliferation. Biochem Biophys Res Commun. 2015;463(3):216\u201321.","journal-title":"Biochem Biophys Res Commun"},{"key":"7582_CR52","doi-asserted-by":"crossref","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021;13(591).","DOI":"10.1126\/scitranslmed.abd8836"},{"issue":"9","key":"7582_CR53","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","volume":"7","author":"AQ Zhang","year":"2023","unstructured":"Zhang AQ, Hostetler A, Chen LE, Mukkamala V, Abraham W, Padilla LT, et al. Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nat Biomed Eng. 2023;7(9):1113\u201328.","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"7582_CR54","doi-asserted-by":"publisher","first-page":"e0383924","DOI":"10.1128\/mbio.03839-24","volume":"16","author":"L Meng","year":"2025","unstructured":"Meng L, Zhao H, Chang S, Li W, Tian Y, Wang R, et al. Engineering of CD8(+) T cells with an HIV-specific synthetic notch receptor to secrete broadly therapeutic antibodies for combining antiviral humoral and cellular immune responses. mBio. 2025;16(4):e0383924.","journal-title":"mBio"},{"issue":"21","key":"7582_CR55","doi-asserted-by":"publisher","first-page":"9712","DOI":"10.1128\/JVI.00852-16","volume":"90","author":"B Liu","year":"2016","unstructured":"Liu B, Zou F, Lu L, Chen C, He D, Zhang X, et al. Chimeric antigen receptor T cells guided by the single-chain fv of a broadly neutralizing antibody specifically and effectively eradicate virus reactivated from latency in CD4+ T Lymphocytes isolated from HIV-1-Infected individuals receiving suppressive combined antiretroviral therapy. J Virol. 2016;90(21):9712\u201324.","journal-title":"J Virol"},{"issue":"2","key":"7582_CR56","first-page":"467","volume":"96","author":"RE Walker","year":"2000","unstructured":"Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood. 2000;96(2):467\u201374.","journal-title":"Blood"},{"issue":"3","key":"7582_CR57","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","volume":"96","author":"RT Mitsuyasu","year":"2000","unstructured":"Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4 zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785\u201393.","journal-title":"Blood"},{"issue":"6","key":"7582_CR58","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1006\/mthe.2002.0611","volume":"5","author":"SG Deeks","year":"2002","unstructured":"Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, et al. A phase ii randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther. 2002;5(6):788\u201397.","journal-title":"Mol Ther"},{"issue":"132","key":"7582_CR59","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4(132):132ra53.","journal-title":"Sci Transl Med"},{"key":"7582_CR60","unstructured":"Safety and anti-HIV activity of autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding Bi-specific anti-gp120 car molecules (LVgp120duoCAR-T) in anti-retroviral drug-treated HIV-1 infection [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04648046."},{"key":"7582_CR61","unstructured":"A pilot study to evaluate the feasibility and safety of cytomegalovirus-specific, anti-HIV chimeric antigen receptor (CMV-HIV CAR) T cells in people living with HIV [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06252402."},{"key":"7582_CR62","unstructured":"The effect of CAR-T cell therapy on the reconstitution of HIV-specific immune function [Internet]. 2017. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03240328."},{"key":"7582_CR63","unstructured":"A phase I trial using third-generation CAR-T-cell therapy in individuals with HIV-1 infection [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04863066."},{"key":"7582_CR64","unstructured":"A Pilot study of T cells genetically modified by zinc finger nucleases SB-728mR and CD4 chimeric antigen receptor in HIV-infected subjects [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03617198."},{"key":"7582_CR65","unstructured":"The efficacy and safety study of CAR-T cells for functional cure in HIV-1\/AIDS patients [Internet]. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06880380."},{"key":"7582_CR66","doi-asserted-by":"crossref","unstructured":"Zhuang AQ, Chen Y, Chen SM, Liu WC, Li Y, Zhang WJ, et al. Current status and challenges in anti-hepatitis B virus agents based on inactivation\/inhibition or elimination of hepatitis B virus covalently closed circular DNA. Viruses. 2023;15(12).","DOI":"10.3390\/v15122315"},{"issue":"11","key":"7582_CR67","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00103-020-03223-7","volume":"63","author":"Z Ivics","year":"2020","unstructured":"Ivics Z, Amberger M, Zahn T, Hildt E. Immunotherapies for the treatment of chronic hepatitis B virus infections-an overview with a focus on car T cells. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2020;63(11):1357\u201364.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"issue":"11","key":"7582_CR68","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1038\/s41375-020-0913-y","volume":"34","author":"C Yang","year":"2020","unstructured":"Yang C, Xie M, Zhang K, Liu H, Liang A, Young KH, et al. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. Leukemia. 2020;34(11):3055\u201359.","journal-title":"Leukemia"},{"issue":"10","key":"7582_CR69","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.cmi.2022.02.042","volume":"28","author":"K Mustafayev","year":"2022","unstructured":"Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect. 2022;28(10):1321\u201327.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"7582_CR70","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5152\/tjg.2018.18263","volume":"29","author":"B Aygen","year":"2018","unstructured":"Aygen B, Demir AM, G\u00fcm\u00fc\u015f M, Karabay O, Kaymako\u011flu S, K\u00f6ksal A, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation: consensus report. Turk J Gastroenterol. 2018;29(3):259\u201369.","journal-title":"Turk J Gastroenterol"},{"issue":"6","key":"7582_CR71","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41409-023-01960-2","volume":"58","author":"S Fu","year":"2023","unstructured":"Fu S, Zhang Q, Jing R, Zu C, Ni F, Lv Y, et al. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. Bone Marrow Transpl. 2023;58(6):701\u201309.","journal-title":"Bone Marrow Transpl"},{"key":"7582_CR72","doi-asserted-by":"publisher","first-page":"751754","DOI":"10.3389\/fimmu.2021.751754","volume":"12","author":"Y Ma","year":"2021","unstructured":"Ma Y, Yang L, Bao Y, Yang Y, Chen L, Zheng M. Case report: post-CAR-T infusion HBV reactivation in two lymphoma patients Despite Entecavir preventive therapy. Front Immunol. 2021;12:751754.","journal-title":"Front Immunol"},{"issue":"9","key":"7582_CR73","doi-asserted-by":"publisher","first-page":"e01515","DOI":"10.14309\/crj.0000000000001515","volume":"11","author":"CJC McKinney","year":"2024","unstructured":"McKinney CJC, Bigelow W, Venkat PG, Shah NL. Post-chimeric antigen receptor T-Cell therapy hepatitis B virus reactivation after 23 months of Entecavir prophylaxis. ACG Case Rep J. 2024;11(9):e01515.","journal-title":"ACG Case Rep J"},{"issue":"1","key":"7582_CR74","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s40425-019-0790-y","volume":"7","author":"J Wei","year":"2019","unstructured":"Wei J, Zhu X, Mao X, Huang L, Meng F, Zhou J. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. J Immunother Cancer. 2019;7(1):315.","journal-title":"J Immunother Cancer"},{"issue":"40","key":"7582_CR75","doi-asserted-by":"publisher","first-page":"14598","DOI":"10.3748\/wjg.v20.i40.14598","volume":"20","author":"HY Sun","year":"2014","unstructured":"Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World J Gastroenterol. 2014;20(40):14598\u2013614.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"7582_CR76","doi-asserted-by":"publisher","first-page":"12309","DOI":"10.1038\/s41598-017-11489-2","volume":"7","author":"M Pokorska-\u015apiewak","year":"2017","unstructured":"Pokorska-\u015apiewak M, Sta\u0144ska-Perka A, Popielska J, O\u0142dakowska A, Coupland U, Zawadka K, et al. Prevalence and predictors of liver disease in HIV-infected children and adolescents. Sci Rep. 2017;7(1):12309.","journal-title":"Sci Rep"},{"issue":"1","key":"7582_CR77","doi-asserted-by":"publisher","first-page":"17066","DOI":"10.1038\/s41598-020-74244-0","volume":"10","author":"X Zhou","year":"2020","unstructured":"Zhou X, Nakashima K, Ito M, Zhang X, Sakai S, Feng C, et al. Prevalence and viral loads of polyomaviruses BKPyV, JCPyV, MCPyV, TSPyV and NJPyV and hepatitis viruses HBV, HCV and HEV in HIV-infected patients in China. Sci Rep. 2020;10(1):17066.","journal-title":"Sci Rep"},{"key":"7582_CR78","doi-asserted-by":"crossref","unstructured":"Salpini R, Malagnino V, Piermatteo L, Mulas T, Alkhatib M, Scutari R, et al. Cryptic HBV replicative activity is frequently revealed in anti-HBc-Positive\/HBsAg-negative patients with HIV infection by highly sensitive molecular assays, and can Be predicted by integrating classical and novel serological HBV markers. Microorganisms. 2020;8(11).","DOI":"10.3390\/microorganisms8111819"},{"issue":"12","key":"7582_CR79","doi-asserted-by":"publisher","first-page":"e13399","DOI":"10.1111\/cmi.13399","volume":"23","author":"L Zhao","year":"2021","unstructured":"Zhao L, Chen F, Quitt O, Festag M, Ringelhan M, Wisskirchen K, et al. Hepatitis B virus envelope proteins can serve as therapeutic targets embedded in the host cell plasma membrane. Cell Microbiol. 2021;23(12):e13399.","journal-title":"Cell Microbiol"},{"key":"7582_CR80","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.coi.2020.04.003","volume":"66","author":"A Bertoletti","year":"2020","unstructured":"Bertoletti A, Tan AT. HBV as a target for CAR or TCR-T cell therapy. Curr Opin Immunol. 2020;66:35\u201341.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"7582_CR81","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jcyt.2018.02.002","volume":"20","author":"RL Kruse","year":"2018","unstructured":"Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, et al. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy. 2018;20(5):697\u2013705.","journal-title":"Cytotherapy"},{"issue":"5","key":"7582_CR82","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.ymthe.2019.02.001","volume":"27","author":"MM Festag","year":"2019","unstructured":"Festag MM, Festag J, Fr\u00e4\u00dfle SP, Asen T, Sacherl J, Schreiber S, et al. Evaluation of a fully human, hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model. Mol Ther. 2019;27(5):947\u201359.","journal-title":"Mol Ther"},{"key":"7582_CR83","doi-asserted-by":"publisher","first-page":"1340619","DOI":"10.3389\/fimmu.2024.1340619","volume":"15","author":"S Schreiber","year":"2024","unstructured":"Schreiber S, Dressler LS, Loffredo-Verde E, Asen T, F\u00e4rber S, Wang W, et al. CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells. Front Immunol. 2024;15:1340619.","journal-title":"Front Immunol"},{"key":"7582_CR84","doi-asserted-by":"publisher","first-page":"1032716","DOI":"10.3389\/fimmu.2022.1032716","volume":"13","author":"M Srivastava","year":"2022","unstructured":"Srivastava M, Copin R, Choy A, Zhou A, Olsen O, Wolf S, et al. Proteogenomic identification of hepatitis B virus (HBV) genotype-specific HLA-I restricted peptides from HBV-positive patient liver tissues. Front Immunol. 2022;13:1032716.","journal-title":"Front Immunol"},{"issue":"1","key":"7582_CR85","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","volume":"10","author":"Q Xiao","year":"2025","unstructured":"Xiao Q, Liu Y, Li T, Wang C, He S, Zhai L, et al. Viral oncogenesis in cancer: from mechanisms to therapeutics. Signal Transduct Target Ther. 2025;10(1):151.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"7582_CR86","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3350\/cmh.2024.0469","volume":"30","author":"A Bertoletti","year":"2024","unstructured":"Bertoletti A, Tan AT. Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: past, present, and future. Editorial on \u201cgenetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting\u201d. Clin Mol Hepatol. 2024;30(4):728\u201334.","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"7582_CR87","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/gutjnl-2023-330577","volume":"73","author":"X Yu","year":"2024","unstructured":"Yu X, Gong Q, Yu D, Chen Y, Jing Y, Zoulim F, et al. Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss. Gut. 2024;73(5):797\u2013809.","journal-title":"Gut"},{"key":"7582_CR88","doi-asserted-by":"crossref","unstructured":"Yu X, Gao Y, Zhang X, Ji L, Fang M, Li M, et al. Hepatitis B: Model systems and therapeutic approaches. J Immunol Res. 2024, 2024;4722047.","DOI":"10.1155\/2024\/4722047"},{"key":"7582_CR89","doi-asserted-by":"publisher","first-page":"703256","DOI":"10.3389\/fimmu.2021.703256","volume":"12","author":"S Alonso-\u00c1lvarez","year":"2021","unstructured":"Alonso-\u00c1lvarez S, Colado E, Moro-Garc\u00eda MA, Alonso-Arias R. Cytomegalovirus in Haematological tumours. Front Immunol. 2021;12:703256.","journal-title":"Front Immunol"},{"issue":"2","key":"7582_CR90","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.2022.281719","volume":"108","author":"G Chen","year":"2023","unstructured":"Chen G, Herr M, Nowak J, Ho C, Almyroudis N, Attwood K, et al. Cytomegalovirus reactivation after CD19 car T-cell therapy is clinically significant. Haematologica. 2023;108(2):615\u201320.","journal-title":"Haematologica"},{"issue":"5","key":"7582_CR91","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/cid\/ciae053","volume":"79","author":"SP Hammond","year":"2024","unstructured":"Hammond SP, Little JS. The clinical significance of cytomegalovirus viremia after chimeric antigen receptor T-Cell therapy. Clin Infect Dis. 2024;79(5):1318\u201319.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"7582_CR92","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","volume":"8","author":"RY Lin","year":"2024","unstructured":"Lin RY, Anderson AD, Natori Y, Raja M, Morris MI, Jimenez AJ, et al. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy. Blood Adv. 2024;8(14):3813\u201322.","journal-title":"Blood Adv"},{"issue":"6","key":"7582_CR93","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/QCO.0000000000001066","volume":"37","author":"E Kampouri","year":"2024","unstructured":"Kampouri E, Reynolds G, Teh BW, Hill JA. Chimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections. Curr Opin Infect Dis. 2024;37(6):526\u201335.","journal-title":"Curr Opin Infect Dis"},{"key":"7582_CR94","doi-asserted-by":"crossref","unstructured":"Sassine J, Siegrist EA, Chemaly RF. Herpesvirus infections after chimeric antigen receptor T-Cell therapy and bispecific antibodies: a review. Viruses. 2025;17(1).","DOI":"10.3390\/v17010133"},{"issue":"2","key":"7582_CR95","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/curroncol29020044","volume":"29","author":"C Zu","year":"2022","unstructured":"Zu C, Xu Y, Wang Y, Zhang M, Zhao H, Fang X, et al. Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for Relapsed\/Refractory multiple myeloma. Curr Oncol. 2022;29(2):490\u201396.","journal-title":"Curr Oncol"},{"issue":"3","key":"7582_CR96","first-page":"e23002","volume":"14","author":"H Bin Dokhi","year":"2022","unstructured":"Bin Dokhi H, Alharbi AO, Ibnouf NH, Alahmari B, Refka MN. Post-CD19 chimeric antigen receptor T-Cell therapy cytomegalovirus Retinitis. Cureus. 2022;14(3):e23002.","journal-title":"Cureus"},{"issue":"3","key":"7582_CR97","first-page":"e56637","volume":"16","author":"L Meller","year":"2024","unstructured":"Meller L, Jagadeesh V, Wilson K, Oca MC, Sestak T, Scott N. Bilateral cytomegalovirus Retinitis after chimeric antigen receptor T-cell therapy for B-cell lymphoma. Cureus. 2024;16(3):e56637.","journal-title":"Cureus"},{"issue":"14","key":"7582_CR98","doi-asserted-by":"publisher","first-page":"e18538","DOI":"10.1111\/jcmm.18538","volume":"28","author":"J Halloun","year":"2024","unstructured":"Halloun J, Maza I, Stern A, Henig I, Akria L, Zohar Y, et al. Cytomegalovirus colitis presenting with lower gastrointestinal bleeding following chimeric antigen receptor-T cell therapy. J Cell Mol Med. 2024;28(14):e18538.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"7582_CR99","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13256-024-04905-5","volume":"19","author":"G Menardi","year":"2025","unstructured":"Menardi G, Castellino A, Castellino C, Bersia ME, Grande E, Fraternali G, et al. Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report. J Med Case Rep. 2025;19(1):27.","journal-title":"J Med Case Rep"},{"issue":"9","key":"7582_CR100","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/CJI.0000000000000388","volume":"44","author":"MR Heldman","year":"2021","unstructured":"Heldman MR, Ma J, Gauthier J, O\u2019Hara RA, Cowan AJ, Yoke LM, et al. CMV and HSV pneumonia after immunosuppressive Agents for treatment of cytokine release syndrome due to chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy. J Immunother. 2021;44(9):351\u201354.","journal-title":"J Immunother"},{"key":"7582_CR101","doi-asserted-by":"publisher","first-page":"1226148","DOI":"10.3389\/fimmu.2023.1226148","volume":"14","author":"J Cheng","year":"2023","unstructured":"Cheng J, Huang J, Cao W, Huang L, Mao X, Chen L, et al. Case report: fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up. Front Immunol. 2023;14:1226148.","journal-title":"Front Immunol"},{"issue":"11","key":"7582_CR102","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1002\/jmv.27257","volume":"93","author":"E Cousin","year":"2021","unstructured":"Cousin E, Belicard F, Michel L, Pronier C, Lassalle N, Lamy T, et al. Severe cytomegalovirus disease with encephalitis after CAR-T cell therapy: a rare but potentially fatal complication. J Med Virol. 2021;93(11):6398\u2013403.","journal-title":"J Med Virol"},{"issue":"1","key":"7582_CR103","doi-asserted-by":"publisher","first-page":"e13733","DOI":"10.1111\/tid.13733","volume":"24","author":"K Santhanakrishnan","year":"2022","unstructured":"Santhanakrishnan K, Yonan N, Iyer K, Callan P, Al-Aloul M, Venkateswaran R. Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review. Transpl Infect Dis. 2022;24(1):e13733.","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"7582_CR104","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1002\/hsr2.322","volume":"4","author":"M Mehdizadeh","year":"2021","unstructured":"Mehdizadeh M, Karami S, Ghaffari Nazari H, Sankanian G, Hamidpour M, Hajifathali A. Immunotherapy with adoptive cytomegalovirus-specific T cells transfer: summarizing latest gene engineering techniques. Health Sci Rep. 2021;4(3):e322.","journal-title":"Health Sci Rep"},{"key":"7582_CR105","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3389\/fmicb.2016.00844","volume":"7","author":"J Proff","year":"2016","unstructured":"Proff J, Walterskirchen C, Brey C, Geyeregger R, Full F, Ensser A, et al. Cytomegalovirus-infected cells resist T cell mediated killing in an HLA-Recognition independent manner. Front Microbiol. 2016;7:844.","journal-title":"Front Microbiol"},{"issue":"1","key":"7582_CR106","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12967-018-1394-x","volume":"16","author":"J Proff","year":"2018","unstructured":"Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains. J Transl Med. 2018;16(1):26.","journal-title":"J Transl Med"},{"key":"7582_CR107","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3389\/fimmu.2019.02711","volume":"10","author":"M Seif","year":"2019","unstructured":"Seif M, Einsele H, L\u00f6ffler J. CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases. Front Immunol. 2019;10:2711.","journal-title":"Front Immunol"},{"key":"7582_CR108","doi-asserted-by":"crossref","unstructured":"Olbrich H, Theobald SJ, Slabik C, Gerasch L, Schneider A, Mach M, et al. Adult and cord blood-derived high-affinity gB-CAR-T cells effectively react against human cytomegalovirus infections. Hum Gene Ther. 2020;31(7\u20138):423\u201339.","DOI":"10.1089\/hum.2019.149"},{"issue":"5","key":"7582_CR109","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/infdis\/jiaa171","volume":"222","author":"A Ali","year":"2020","unstructured":"Ali A, Chiuppesi F, Nguyen M, Hausner MA, Nguyen J, Kha M, et al. Chimeric antigen receptors targeting human cytomegalovirus. J Infect Dis. 2020;222(5):853\u201362.","journal-title":"J Infect Dis"},{"key":"7582_CR110","doi-asserted-by":"crossref","unstructured":"Wang X, Urak R, Walter M, Guan M, Han T, Vyas V, et al. Large-scale manufacturing and characterization of CMV-CD19CAR T cells. J Immunother Cancer. 2022;10(1).","DOI":"10.1136\/jitc-2021-003461"},{"issue":"13","key":"7582_CR111","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1158\/1078-0432.CCR-14-2920","volume":"21","author":"X Wang","year":"2015","unstructured":"Wang X, Wong CW, Urak R, Mardiros A, Budde LE, Chang WC, et al. CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-Specific T cells. Clin Cancer Res. 2015;21(13):2993\u20133002.","journal-title":"Clin Cancer Res"},{"key":"7582_CR112","unstructured":"Pilot\/Feasibility study of CMV-Specific CD19-CAR T cells Plus CMV-MVA Triplex following autologous hematopoietic stem cell Transplantation for patients with Intermediate or high Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL) [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05432635."},{"key":"7582_CR113","unstructured":"A Pilot\/Feasibility study of autologous CMV-Specific CD19-CAR T cells Plus CMV-MVA Triplex vaccine in patients with Intermediate or high Grade B-Lineage Non-Hodgkin Lymphoma [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05801913."},{"key":"7582_CR114","unstructured":"Pilot\/Feasibility study of CMV-Specific CD19-CAR T cells Plus CMV-MVA Triplex following matched related Allogeneic hematopoietic cell Transplantation for patients with high-risk acute lymphoblastic leukemia [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06735690."},{"key":"7582_CR115","unstructured":"Administration of HER2 chimeric antigen receptor expressing CMV-Specific cytotoxic T cells Ins patients with Glioblastoma Multiforme (HERT-GBM) [Internet]. 2010. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01109095."},{"key":"7582_CR116","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.leukres.2015.12.003","volume":"41","author":"L Zhou","year":"2016","unstructured":"Zhou L, Liu X, Wang X, Sun Z, Song XT. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia. Leuk Res. 2016;41:76\u201384.","journal-title":"Leuk Res"},{"key":"7582_CR117","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.omtm.2022.04.007","volume":"25","author":"M Guan","year":"2022","unstructured":"Guan M, Lim L, Holguin L, Han T, Vyas V, Urak R, et al. Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine. Mol Ther Methods Clin Dev. 2022;25:344\u201359.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"7582_CR118","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1086\/367988","volume":"187","author":"H Kimura","year":"2003","unstructured":"Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187(4):527\u201333.","journal-title":"J Infect Dis"},{"issue":"4","key":"7582_CR119","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ped4.12350","volume":"6","author":"Y Luo","year":"2022","unstructured":"Luo Y, Wei A, Wang B, Zhu G, Zhang R, Jia C, et al. Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein-Barr virus infection. Pediatr Investig. 2022;6(4):250\u201359.","journal-title":"Pediatr Investig"},{"issue":"7","key":"7582_CR120","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1128\/JVI.79.7.4415-4424.2005","volume":"79","author":"N Ahsan","year":"2005","unstructured":"Ahsan N, Kanda T, Nagashima K, Takada K. Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production. J Virol. 2005;79(7):4415\u201324.","journal-title":"J Virol"},{"key":"7582_CR121","doi-asserted-by":"publisher","first-page":"1451977","DOI":"10.3389\/fimmu.2024.1451977","volume":"15","author":"S Yan","year":"2024","unstructured":"Yan S, Ming X, Zhu X, Xiao Y. Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease. Front Immunol. 2024;15:1451977.","journal-title":"Front Immunol"},{"issue":"9","key":"7582_CR122","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jcyt.2023.04.003","volume":"25","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Lyu H, Guo R, Cao X, Feng J, Jin X, et al. Epstein\u2012Barr virus-associated cellular immunotherapy. Cytotherapy. 2023;25(9):903\u201312.","journal-title":"Cytotherapy"},{"key":"7582_CR123","doi-asserted-by":"publisher","first-page":"734471","DOI":"10.3389\/fimmu.2021.734471","volume":"12","author":"X Cui","year":"2021","unstructured":"Cui X, Snapper CM. Epstein Barr Virus: development of vaccines and immune cell therapy for EBV-associated diseases. Front Immunol. 2021;12:734471.","journal-title":"Front Immunol"},{"issue":"6","key":"7582_CR124","doi-asserted-by":"publisher","first-page":"468","DOI":"10.7555\/JBR.28.20140066","volume":"28","author":"X Tang","year":"2014","unstructured":"Tang X, Zhou Y, Li W, Tang Q, Chen R, Zhu J, et al. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. J Biomed Res. 2014;28(6):468\u201375.","journal-title":"J Biomed Res"},{"issue":"3","key":"7582_CR125","first-page":"229","volume":"43","author":"HZ He","year":"2022","unstructured":"He HZ, Xing YY, Zhang Y, Xu YX, Tian Z, Xing HY, et al. Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen. Zhonghua Xue Ye Xue Za Zhi. 2022;43(3):229\u201334.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"7582_CR126","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","volume":"18","author":"C Slabik","year":"2020","unstructured":"Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V, et al. CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol Ther Oncolytics. 2020;18:504\u201324.","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"7582_CR127","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12967-025-06188-w","volume":"23","author":"J Wang","year":"2025","unstructured":"Wang J, Wang H, Ding Y, Cao N, Nan F, Wu F, et al. Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T. J Transl Med. 2025;23(1):171.","journal-title":"J Transl Med"},{"key":"7582_CR128","doi-asserted-by":"publisher","first-page":"1103695","DOI":"10.3389\/fimmu.2023.1103695","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wang T, Zhu X, Lu Y, Li M, Huang Z, et al. GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies. Front Immunol. 2023;14:1103695.","journal-title":"Front Immunol"},{"key":"7582_CR129","doi-asserted-by":"publisher","first-page":"1086433","DOI":"10.3389\/fimmu.2023.1086433","volume":"14","author":"T Braun","year":"2023","unstructured":"Braun T, Pruene A, Darguzyte M, Vom Stein AF, Nguyen PH, Wagner DL, et al. Non-viral TRAC-knocked-in CD19(KI)CAR-T and gp350(KI)CAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: in vivo cellular dynamics and potency. Front Immunol. 2023;14:1086433.","journal-title":"Front Immunol"},{"issue":"12","key":"7582_CR130","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.21037\/tp-24-292","volume":"13","author":"Y Liu","year":"2024","unstructured":"Liu Y, Cai J, Wang T, Wang J, Tang Y, Wan X, et al. Glycoprotein 350-targeted chimeric antigen receptor T-cell therapy for nonneoplastic chronic active Epstein-Barr virus infection: a case report. Transl Pediatr. 2024;13(12):2305\u201310.","journal-title":"Transl Pediatr"},{"issue":"7953","key":"7582_CR131","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023;615(7953):687\u201396.","journal-title":"Nature"},{"issue":"1","key":"7582_CR132","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40164-025-00631-w","volume":"14","author":"T Kaeuferle","year":"2025","unstructured":"Kaeuferle T, Zwermann M, Stoll N, Ferrada-Ernst P, Jablonowski L, Zeidler R, et al. All-in-one CRISPR\/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone. Exp Hematol Oncol. 2025;14(1):40.","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"7582_CR133","first-page":"925","volume":"53","author":"Y Chen","year":"2018","unstructured":"Chen Y, Chen RJ, Huang XC, Tang GX, Kuai XW, Zhang MJ, et al. Construction of latent membrane protein 2A chimeric antigen receptor-T cells and their lethal effects on nasopharyngeal carcinoma cells. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018;53(12):925\u201330.","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"7582_CR134","doi-asserted-by":"crossref","unstructured":"Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, et al. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 2018;3(4).","DOI":"10.1172\/jci.insight.97805"},{"issue":"10","key":"7582_CR135","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1084\/jem.20040191","volume":"199","author":"J Tellam","year":"2004","unstructured":"Tellam J, Connolly G, Green KJ, Miles JJ, Moss DJ, Burrows SR, et al. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med. 2004;199(10):1421\u201331.","journal-title":"J Exp Med"},{"key":"7582_CR136","doi-asserted-by":"crossref","unstructured":"Dragon AC, Zimmermann K, Nerreter T, Sandfort D, Lahrberg J, Kl\u00f6\u00df S, et al. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-000736"},{"issue":"2","key":"7582_CR137","doi-asserted-by":"publisher","first-page":"200814","DOI":"10.1016\/j.omton.2024.200814","volume":"32","author":"DH Quach","year":"2024","unstructured":"Quach DH, Ganesh HR, Briones YD, Nouraee N, Ma A, Hadidi YF, et al. Rejection resistant CD30. CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30(+) lymphoma. Mol Ther Oncol. 2024;32(2):200814.","journal-title":"Mol Ther Oncol"},{"key":"7582_CR138","doi-asserted-by":"publisher","first-page":"1433432","DOI":"10.3389\/fonc.2024.1433432","volume":"14","author":"R Mohty","year":"2024","unstructured":"Mohty R, Lazaryan A. \u201cOff-the-shelf\u201d allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges. Front Oncol. 2024;14:1433432.","journal-title":"Front Oncol"},{"key":"7582_CR139","unstructured":"A phase 1 study Evaluating the safety and activity of Allogeneic CD30 chimeric antigen receptor Epstein-Barr virus-specific T Lymphocytes (CD30.CAR-EBVSTs) in patients with Relapsed or Refractory CD30-positive lymphomas [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04288726."},{"key":"7582_CR140","unstructured":"A phase 1 study Evaluating the safety and activity of Allogeneic CD30 chimeric antigen receptor Epstein-Barr virus-specific T Lymphocytes (CD30.CAR-EBVSTs) in patients with Relapsed or Refractory CD30-positive lymphomas [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04952584."},{"key":"7582_CR141","unstructured":"A phase 1 study to Evaluate the safety and preliminary efficacy of ATA3219, Allogeneic anti-CD19 chimeric antigen receptor T-cell (car t) therapy, in subjects with systemic lupus erythematosus [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06429800."},{"key":"7582_CR142","unstructured":"A phase 1 study Evaluating the safety and efficacy of BRG01 in subjects with Relapsed\/Metastatic EBV-positive nasopharyngeal carcinoma [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05864924."},{"key":"7582_CR143","unstructured":"Clinical trial for the safety and efficacy of sequential of LMP1 CAR-T for patients with LMP1 positive infectious Diseases and hematological malignancies [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04657965."},{"key":"7582_CR144","unstructured":"A new Efficient EBV AssociatedTechnologies of T cells in treating malignant tumors and clinical application [Internet]. 2016. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02980315."},{"key":"7582_CR145","unstructured":"Clinical study on the safety and efficacy of EBV CAR-T\/TCR-T cells in the treatment of Recurrent\/Refractory EBV positive nasopharyngeal carcinoma [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05587543.."},{"issue":"1","key":"7582_CR146","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"7582_CR147","doi-asserted-by":"publisher","first-page":"1253395","DOI":"10.3389\/fimmu.2023.1253395","volume":"14","author":"FH Rothemejer","year":"2023","unstructured":"Rothemejer FH, Lauritsen NP, S\u00f8gaard OS, Tolstrup M. Strategies for enhancing CAR T cell expansion and persistence in HIV infection. Front Immunol. 2023;14:1253395.","journal-title":"Front Immunol"},{"issue":"1","key":"7582_CR148","doi-asserted-by":"publisher","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","volume":"10","author":"C Belin","year":"2020","unstructured":"Belin C, Devic P, Ayrignac X, Dos Santos A, Paix A, Sirven-Villaros L, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep. 2020;10(1):18997.","journal-title":"Sci Rep"},{"issue":"1","key":"7582_CR149","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","volume":"7","author":"MR Cook","year":"2023","unstructured":"Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, et al. Toxicity and efficacy of car T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7(1):32\u201339.","journal-title":"Blood Adv"},{"issue":"12","key":"7582_CR150","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1084\/jem.20071030","volume":"204","author":"B Serafini","year":"2007","unstructured":"Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12):2899\u2013912.","journal-title":"J Exp Med"},{"issue":"9","key":"7582_CR151","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3174\/ajnr.A7945","volume":"44","author":"N Soni","year":"2023","unstructured":"Soni N, Ora M, Singh R, Mehta P, Agarwal A, Bathla G. Unpacking the CNS manifestations of Epstein-Barr virus: an imaging perspective. AJNR Am J Neuroradiol. 2023;44(9):1002\u201308.","journal-title":"AJNR Am J Neuroradiol"},{"key":"7582_CR152","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fcimb.2019.00362","volume":"9","author":"C Wallet","year":"2019","unstructured":"Wallet C, De Rovere M, Van Assche J, Daouad F, De Wit S, Gautier V, et al. Microglial cells: the main HIV-1 reservoir in the brain. Front Cell Infect Microbiol. 2019;9:362.","journal-title":"Front Cell Infect Microbiol"},{"key":"7582_CR153","doi-asserted-by":"crossref","unstructured":"Barber-Axthelm IM, Barber-Axthelm V, Sze KY, Zhen A, Suryawanshi GW, Chen IS, et al. Stem cell-derived CAR T cells traffic to HIV reservoirs in macaques. JCI Insight. 2021;6(1).","DOI":"10.1172\/jci.insight.141502"},{"issue":"1","key":"7582_CR154","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"7582_CR155","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","volume":"22","author":"W Luo","year":"2022","unstructured":"Luo W, Li C, Zhang Y, Du M, Kou H, Lu C, et al. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis. BMC Cancer. 2022;22(1):98.","journal-title":"BMC Cancer"},{"key":"7582_CR156","doi-asserted-by":"publisher","first-page":"1488527","DOI":"10.3389\/fcimb.2024.1488527","volume":"14","author":"F Yu","year":"2024","unstructured":"Yu F, Zhu Y, Li S, Hao L, Li N, Ye F, et al. Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies. Front Cell Infect Microbiol. 2024;14:1488527.","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"7582_CR157","doi-asserted-by":"publisher","first-page":"106932","DOI":"10.4254\/wjh.v17.i6.106932","volume":"17","author":"SF Li","year":"2025","unstructured":"Li SF, Ouyang X, Feng S, Wan MZ, Zhou KN, Wen BY, et al. Oncohepatology: navigating liver injury in the era of modern cancer therapy. World J Hepatol. 2025;17(6):106932.","journal-title":"World J Hepatol"},{"issue":"5","key":"7582_CR158","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s12185-023-03660-5","volume":"118","author":"JI Kawada","year":"2023","unstructured":"Kawada JI, Ito Y, Ohshima K, Yamada M, Kataoka S, Muramatsu H, et al. Updated guidelines for chronic active Epstein-Barr virus disease. Int J Hematol. 2023;118(5):568\u201376.","journal-title":"Int J Hematol"},{"issue":"2","key":"7582_CR159","doi-asserted-by":"publisher","first-page":"160","DOI":"10.33160\/yam.2022.05.003","volume":"65","author":"S Ikeda","year":"2022","unstructured":"Ikeda S, Sugihara T, Kihara T, Hoshino Y, Matsuki Y, Nagahara T, et al. Chronic active Epstein-Barr virus infection indistinguishable from autoimmune hepatitis: a case report. Yonago Acta Med. 2022;65(2):160\u201365.","journal-title":"Yonago Acta Med"},{"key":"7582_CR160","doi-asserted-by":"publisher","first-page":"825806","DOI":"10.3389\/fimmu.2022.825806","volume":"13","author":"K Nakajima","year":"2022","unstructured":"Nakajima K, Hiejima E, Nihira H, Kato K, Honda Y, Izawa K, et al. Case report: a Case of Epstein-Barr virus-associated acute liver failure requiring hematopoietic cell Transplantation after emergent liver Transplantation. Front Immunol. 2022;13:825806.","journal-title":"Front Immunol"},{"issue":"1","key":"7582_CR161","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/INF.0000000000003738","volume":"42","author":"W Ou","year":"2023","unstructured":"Ou W, Zhao Y, Wei A, Ma H, Zhang L, Lian H, et al. Chronic active Epstein-Barr virus infection with central nervous system involvement in children: a clinical study of 22 cases. Pediatr Infect Dis J. 2023;42(1):20\u201326.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"7582_CR162","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/s41564-023-01349-3","volume":"8","author":"RT Veenhuis","year":"2023","unstructured":"Veenhuis RT, Abreu CM, Costa PAG, Ferreira EA, Ratliff J, Pohlenz L, et al. Monocyte-derived macrophages contain persistent latent HIV reservoirs. Nat Microbiol. 2023;8(5):833\u201344.","journal-title":"Nat Microbiol"},{"key":"7582_CR163","doi-asserted-by":"publisher","first-page":"611366","DOI":"10.3389\/fimmu.2021.611366","volume":"12","author":"Z Yan","year":"2021","unstructured":"Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol. 2021;12:611366.","journal-title":"Front Immunol"},{"issue":"23","key":"7582_CR164","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","volume":"130","author":"AE Obstfeld","year":"2017","unstructured":"Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood. 2017;130(23):2569\u201372.","journal-title":"Blood"},{"issue":"1","key":"7582_CR165","first-page":"52","volume":"10","author":"S Maleki","year":"2024","unstructured":"Maleki S, Esmaeili Z, Seighali N, Shafiee A, Namin SM, Zavareh MAT, et al. Cardiac adverse events after chimeric antigen receptor (car) T cell therapies: an updated systematic review and meta-analysis. Cardiooncology. 2024;10(1):52.","journal-title":"Cardiooncology"},{"key":"7582_CR166","doi-asserted-by":"publisher","first-page":"1090103","DOI":"10.3389\/fcvm.2023.1090103","volume":"10","author":"M Camilli","year":"2023","unstructured":"Camilli M, Maggio L, Tinti L, Lamendola P, Lanza GA, Crea F, et al. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: a clinical appraisal. Front Cardiovasc Med. 2023;10:1090103.","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"7582_CR167","doi-asserted-by":"publisher","first-page":"e 1154","DOI":"10.1002\/cti2.1154","volume":"9","author":"H Liu","year":"2020","unstructured":"Liu H, Ma Y, Yang C, Xia S, Pan Q, Zhao H, et al. Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer. Clin Transl Immunol. 2020;9(10):e 1154.","journal-title":"Clin Transl Immunol"},{"issue":"8","key":"7582_CR168","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","volume":"31","author":"AR Haas","year":"2023","unstructured":"Haas AR, Golden RJ, Litzky LA, Engels B, Zhao L, Xu F, et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed car T cells. Mol Ther. 2023;31(8):2309\u201325.","journal-title":"Mol Ther"},{"key":"7582_CR169","doi-asserted-by":"crossref","unstructured":"Kanno H, Osada T, Tateishi A. Establishment of Epstein-Barr virus (EBV) latent gene-expressing T-Cell lines with an expression vector harboring EBV nuclear antigen 1. Microorganisms. 2023;11(11).","DOI":"10.3390\/microorganisms11112624"},{"issue":"4","key":"7582_CR170","doi-asserted-by":"publisher","first-page":"55","DOI":"10.32607\/20758251-2011-3-4-55-65","volume":"3","author":"MM Prokofjeva","year":"2011","unstructured":"Prokofjeva MM, Spirin PV, Yanvarev DV, Ivanov AV, Novikov MS, Stepanov OA, et al. Screening of potential HIV-1 Inhibitors\/Replication blockers using secure lentiviral in vitro system. Acta Naturae. 2011;3(4):55\u201365.","journal-title":"Acta Naturae"},{"issue":"2","key":"7582_CR171","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.exphem.2015.10.003","volume":"44","author":"N Uchida","year":"2016","unstructured":"Uchida N, Green R, Ballantine J, Skala LP, Hsieh MM, Tisdale JF. Kinetics of lentiviral vector transduction in human CD34(+) cells. Exp Hematol. 2016;44(2):106\u201315.","journal-title":"Exp Hematol"},{"issue":"2","key":"7582_CR172","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, et al. Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng. 2022;6(2):118\u201328.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"7582_CR173","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12910-021-00716-1","volume":"22","author":"A Gilbertson","year":"2021","unstructured":"Gilbertson A, Tucker JD, Dub\u00e9 K, Dijkstra M, Rennie S. Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection. BMC Med Ethics. 2021;22(1):169.","journal-title":"BMC Med Ethics"},{"issue":"1","key":"7582_CR174","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12910-022-00741-8","volume":"23","author":"J Kanazawa","year":"2022","unstructured":"Kanazawa J, Gianella S, Concha-Garcia S, Taylor J, Kaytes A, Christensen C, et al. Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States. BMC Med Ethics. 2022;23(1):2.","journal-title":"BMC Med Ethics"},{"issue":"5","key":"7582_CR175","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/bcp.16047","volume":"90","author":"P Celis","year":"2024","unstructured":"Celis P, Farinelli G, Hidalgo-Simon A, Meij P, Tihaya M, Sch\u00fcssler-Lenz M, et al. EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells. Br J Clin Pharmacol. 2024;90(5):1203\u201312.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"7582_CR176","doi-asserted-by":"publisher","first-page":"104337","DOI":"10.1016\/j.drudis.2025.104337","volume":"30","author":"de Haart K","year":"2025","unstructured":"de Haart K, Asao K, Ataher Q, Geier J, Hillen J, Huang K, et al. Long-term follow-up after authorization of gene therapy: leveraging real-world data. Drug Discov Today. 2025;30(5):104337.","journal-title":"Drug Discov Today"},{"key":"7582_CR177","doi-asserted-by":"crossref","unstructured":"Karasawa H, Mizoguchi H, Choi B, Hsieh CL, Miyano M, Moriya Y, et al. Regulatory insights on advanced CAR\u2013T cell products, AAV-based gene therapies, and medical care\/practice in cell and gene therapies: report from the 6th Asia Partnership Conference of Regenerative Medicine. Regen Ther. 2024;26:967\u201380.","DOI":"10.1016\/j.reth.2024.09.015"},{"key":"7582_CR178","doi-asserted-by":"publisher","first-page":"1190016","DOI":"10.3389\/fmed.2023.1190016","volume":"10","author":"P Salmikangas","year":"2023","unstructured":"Salmikangas P, Carlsson B, Klumb C, Reimer T, Thirstrup S. Potency testing of cell and gene therapy products. Front Med (Lausanne). 2023;10:1190016.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"7582_CR179","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14712598.2024.2371042","volume":"24","author":"H Mizoguchi","year":"2024","unstructured":"Mizoguchi H, Fleischmann T, Komuro M, Hirai T, Ikeda A, Saito K, et al. Comparative analysis of GMO regulatory requirements for AAV vectors in the EU and Japan focusing on the shedding data and containment measures. Expert Opin Biol Ther. 2024;24(6):529\u201342.","journal-title":"Expert Opin Biol Ther"},{"key":"7582_CR180","doi-asserted-by":"crossref","unstructured":"Katsarou A, Sj\u00f6strand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci Transl Med. 2021 1962;13(623):eabh.","DOI":"10.1126\/scitranslmed.abh1962"},{"key":"7582_CR181","doi-asserted-by":"crossref","unstructured":"Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci. 2016, 113(48).","DOI":"10.1073\/pnas.1610544113"},{"issue":"74","key":"7582_CR182","doi-asserted-by":"publisher","first-page":"eabl 3995","DOI":"10.1126\/sciimmunol.abl3995","volume":"7","author":"Q Xiao","year":"2022","unstructured":"Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS, Su X. Size-dependent activation of CAR-T cells. Sci Immunol. 2022;7(74):eabl 3995.","journal-title":"Sci Immunol"},{"issue":"4","key":"7582_CR183","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.ymthe.2024.02.026","volume":"32","author":"MA Carrillo","year":"2024","unstructured":"Carrillo MA, Zhen A, Mu W, Rezek V, Martin H, Peterson CW, et al. Stem cell-derived car T cells show greater persistence, trafficking, and viral control compared to ex vivo transduced CAR T cells. Mol Ther. 2024;32(4):1000\u201315.","journal-title":"Mol Ther"},{"issue":"8","key":"7582_CR184","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/mt.2015.102","volume":"23","author":"A Zhen","year":"2015","unstructured":"Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther. 2015;23(8):1358\u201367.","journal-title":"Mol Ther"},{"issue":"6","key":"7582_CR185","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41423-020-0470-3","volume":"17","author":"L Wu","year":"2020","unstructured":"Wu L, Wei Q, Brzostek J, Gascoigne NRJ. Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells. Cell Mol Immunol. 2020;17(6):600\u201312.","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"7582_CR186","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545\u201358.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"7582_CR187","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847\u201356.","journal-title":"Nat Biotechnol"},{"issue":"15","key":"7582_CR188","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted car T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186(15):3148\u201365.e20.","journal-title":"Cell"},{"issue":"5","key":"7582_CR189","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7(5):759\u201372.","journal-title":"Cancer Immunol Res"},{"issue":"48","key":"7582_CR190","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016;113(48):E7788\u2013e97.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7582_CR191","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12964-023-01354-3","volume":"21","author":"M Luo","year":"2023","unstructured":"Luo M, Gong W, Zhang Y, Li H, Ma D, Wu K, et al. New insights into the stemness of adoptively transferred T cells by \u03b3c family cytokines. Cell Commun Signal. 2023;21(1):347.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"7582_CR192","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","volume":"15","author":"M Shi","year":"2024","unstructured":"Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial. Nat Commun. 2024;15(1):3371.","journal-title":"Nat Commun"},{"issue":"640","key":"7582_CR193","doi-asserted-by":"publisher","first-page":"eabn 2231","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med. 2022;14(640):eabn 2231.","journal-title":"Sci Transl Med"},{"issue":"6","key":"7582_CR194","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/hep.25875","volume":"56","author":"C Ji","year":"2012","unstructured":"Ji C, Sastry KS, Tiefenthaler G, Cano J, Tang T, Ho ZZ, et al. Targeted delivery of interferon-\u03b1 to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology. 2012;56(6):2027\u201338.","journal-title":"Hepatology"},{"issue":"1","key":"7582_CR195","doi-asserted-by":"publisher","first-page":"2546404","DOI":"10.1080\/2162402X.2025.2546404","volume":"14","author":"F Wang","year":"2025","unstructured":"Wang F, Li J, Huang Y, Yan F, Gao H, Zhou W, et al. CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183-91\/HLA-A *0201 exhibit potent activity against HBV-HCC. Oncoimmunology. 2025;14(1):2546404.","journal-title":"Oncoimmunology"},{"issue":"1","key":"7582_CR196","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-019-0763-0","volume":"12","author":"D Liu","year":"2019","unstructured":"Liu D, Zhao J, Song Y. Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol. 2019;12(1):69.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"7582_CR197","doi-asserted-by":"publisher","first-page":"14455","DOI":"10.1038\/s41598-017-14823-w","volume":"7","author":"IC Chen","year":"2017","unstructured":"Chen IC, Chiu YK, Yu CM, Lee CC, Tung CP, Tsou YL, et al. High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries. Sci Rep. 2017;7(1):14455.","journal-title":"Sci Rep"},{"key":"7582_CR198","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s42003-019-0551-y","volume":"2","author":"LD Goldstein","year":"2019","unstructured":"Goldstein LD, Chen YJ, Wu J, Chaudhuri S, Hsiao YC, Schneider K, et al. Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies. Commun Biol. 2019;2:304.","journal-title":"Commun Biol"},{"key":"7582_CR199","doi-asserted-by":"crossref","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med. 2019;11(499).","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"7582_CR200","doi-asserted-by":"publisher","first-page":"106329","DOI":"10.1016\/j.phrs.2022.106329","volume":"182","author":"SM Sagnella","year":"2022","unstructured":"Sagnella SM, White AL, Yeo D, Saxena P, van Zandwijk N, Rasko JEJ. Locoregional delivery of CAR-T cells in the clinic. Pharmacol Res. 2022;182:106329.","journal-title":"Pharmacol Res"},{"issue":"6379","key":"7582_CR201","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018;359(6379):1037\u201342.","journal-title":"Science"},{"issue":"625","key":"7582_CR202","doi-asserted-by":"publisher","first-page":"eabg 7565","DOI":"10.1126\/scitranslmed.abg7565","volume":"13","author":"PJ Aspuria","year":"2021","unstructured":"Aspuria PJ, Vivona S, Bauer M, Semana M, Ratti N, McCauley S, et al. An orthogonal IL-2 and IL-2R\u03b2 system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. Sci Transl Med. 2021;13(625):eabg 7565.","journal-title":"Sci Transl Med"},{"issue":"7","key":"7582_CR203","doi-asserted-by":"publisher","first-page":"e0254148","DOI":"10.1371\/journal.pone.0254148","volume":"16","author":"J Kanazawa","year":"2021","unstructured":"Kanazawa J, Gianella S, Concha-Garcia S, Taylor J, Kaytes A, Christensen C, et al. Ethical and practical considerations for interventional HIV cure-related research at the end-of-life: a qualitative study with key stakeholders in the United States. PLoS One. 2021;16(7):e0254148.","journal-title":"PLoS One"},{"issue":"1","key":"7582_CR204","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12910-022-00780-1","volume":"23","author":"K Dub\u00e9","year":"2022","unstructured":"Dub\u00e9 K, Kanazawa J, Patel H, Louella M, Sylla L, Sheehy J, et al. Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States. BMC Med Ethics. 2022;23(1):39.","journal-title":"BMC Med Ethics"},{"issue":"29","key":"7582_CR205","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.1312789111","volume":"111","author":"PR Kumaresan","year":"2014","unstructured":"Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A. 2014;111(29):10660\u201365.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"7582_CR206","doi-asserted-by":"publisher","first-page":"e2318003121","DOI":"10.1073\/pnas.2318003121","volume":"121","author":"RL Paterson","year":"2024","unstructured":"Paterson RL, La Manna MP, Arena De Souza V, Walker A, Gibbs-Howe D, Kulkarni R, et al. An HLA-E-targeted TCR bispecific molecule redirects T cell immunity against Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2024;121(19):e2318003121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"664","key":"7582_CR207","doi-asserted-by":"publisher","first-page":"eabh 1209","DOI":"10.1126\/scitranslmed.abh1209","volume":"14","author":"M Seif","year":"2022","unstructured":"Seif M, Kakoschke TK, Ebel F, Bellet MM, Trinks N, Renga G, et al. CAR T cells targeting aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models. Sci Transl Med. 2022;14(664):eabh 1209.","journal-title":"Sci Transl Med"},{"issue":"3","key":"7582_CR208","doi-asserted-by":"publisher","first-page":"e1004671","DOI":"10.1371\/journal.ppat.1004671","volume":"11","author":"van Meijgaarden Ke","year":"2015","unstructured":"Van Meijgaarden KE, Haks MC, Caccamo N, Dieli F, Ottenhoff TH, Joosten SA. Human CD8+ T\u2013cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA\u2013E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T\u2013cell subset. PLoS Pathog. 2015;11(3):e1004671.","journal-title":"PLoS Pathog"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07582-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07582-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07582-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:04:50Z","timestamp":1770653090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07582-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":208,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7582"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07582-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}